Physician profile
Thomas E Johnson
NPI 1477578680
$2,242.38
in general payments reported to CMS, 2019-2025
13 companies · $27.12 in 2025
The $27.12 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $137 · 2021: $125 · 2022: $143 · 2023: $509 · 2024: $1,125 · 2025: $27.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $661.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,033.85 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $423.02 | 2020-2023 | Tepezza |
| Genentech USA, INC. | $204.50 | 2019-2021 | |
| Alcon Vision LLC | $148.42 | 2023 | Clareon |
| Poriferous LLC | $116.34 | 2022 | |
| Abbvie INC. | $91.56 | 2024 | |
| Allergan, INC. | $83.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $62.43 | 2020-2023 | Acthar |
| Argenx US, INC. | $27.12 | 2025 | Vyvgart Hytrulo |
| Biotissue Holdings INC. | $23.93 | 2023 | |
| Katalyst Surgical, LLC | $15.19 | 2023 | |
| Mallinckrodt Enterprises LLC | $12.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.